PH vs SPRY · P/E 28, rev $19.85B vs rev $89.1M
Parker-Hannifin Corporation (PH) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
PH currently screens at market cap $91.89B and trailing P/E 27.7. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the PH and SPRY stock pages for the full models.
Not investment advice.